Hello! Welcome to visit Ausun Pharmaceutical

Zhejiang Ausun Pharmaceutical Co., Ltd.
您的当前位置: Home > News > Industry News Industry News / Company introduction

New anti-cancer drug test results are expected to end the traditional chemotherapy

文章来源:国家统计局 发布时间:2016-01-23 12:56:25 浏览次数:Read 【字体:

Ibrutinib kills the cells in patients with chronic lymphocytic leukemia, and it will be another option for conventional chemotherapy. Ibrutinib kills the cells in patients with chronic lymphocytic leukemia, and it will be another option for conventional chemotherapy.

Beijing time 5 news, according to foreign media reports, of a novel anticancer drug breakthrough international test, let researchers see new hope in the fight against leukemia, an Australian doctor pointed out that it will put an end to the traditional chemotherapy.

Of 391 patients of test results showed that the anticancer drug ibrutinib those and a slow development of leukemia type, chronic lymphocytic leukemia (CLL) as a chance to fight in patients who survived up to 90%, and traditional therapy, the survival rate was only 81%. In addition, it has less damage to the body than traditional chemotherapy methods, and it is a choice for those cancer cells that have become resistant to chemotherapy. The results also showed that 40% of patients in the treatment of one year of remission of the disease, compared with the traditional chemotherapy, this figure is only 4%. This experiment prompted Australia Melbourne Peter McCallum cancer center of Cowen - Tam, trust, ibrutinib will eventually replace chemotherapy become the main method for the treatment of leukemia patients. He said: "we may no longer need chemotherapy."

Tamm says patients who participated in the international trial responded to the drug faster than chemotherapy, and showed fewer side effects. It is particularly encouraging that patients who have not been used or are resistant to chemotherapy have another choice. "These patients have no choice," says Tamm, co-author of a paper published in the new England Journal of medicine. When chemotherapy is lost, the drug is really good." Ibrutinib has a role in the ability to produce an enzyme that is essential for the survival of leukemia, which is now being accelerated in the United States, and may be able to buy it in Australia a year later.

Although chronic lymphocytic leukemia is the most common cancer types, but it is the most common of a type of blood cancer, and the older, the more prone to the disease. About 80% of the newly diagnosed cases are more than 60 years old. The disease is more common in men than in women, and because of its slow development, many people don't even show any signs of symptoms at the early stage. Tam said that next year the drug in Australia, every year in the country will have hundreds of people benefit from it, however, unless it can enter the Australian drug benefit program within 2 to 3 years, otherwise most people will afford the high cost of the drug.